# EDGAR Filing Document

**Accession Number:** 0001113423
**File Stem:** 0001493152-25-025595
**Filing Date:** 2025-12
**Character Count:** 14531
**Document Hash:** 68a7bdaf2460c034d3f4237749dbce53
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-25-025595.hdr.sgml**: 20251201

**ACCESSION NUMBER**: 0001493152-25-025595

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 3

**CONFORMED PERIOD OF REPORT**: 20251201

**FILED AS OF DATE**: 20251201

**DATE AS OF CHANGE**: 20251201

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** COSCIENS Biopharma Inc.
- **CENTRAL INDEX KEY:** 0001113423
- **STANDARD INDUSTRIAL CLASSIFICATION:** PERFUMES, COSMETICS & OTHER TOILET PREPARATIONS [2844]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 000000000
- **STATE OF INCORPORATION:** A6
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38064
- **FILM NUMBER:** 251540535

**BUSINESS ADDRESS:**
- **STREET 1:** C/O NORTON ROSE FULBRIGHT CANADA LLP
- **STREET 2:** 222 BAY STREET, SUITE 3000, PO BOX 53
- **CITY:** TORONTO
- **STATE:** A6
- **ZIP:** M5K 1E7
- **BUSINESS PHONE:** 843-900-3201

**MAIL ADDRESS:**
- **STREET 1:** C/O NORTON ROSE FULBRIGHT CANADA LLP
- **STREET 2:** 222 BAY STREET, SUITE 3000, PO BOX 53
- **CITY:** TORONTO
- **STATE:** A6
- **ZIP:** M5K 1E7

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Aeterna Zentaris Inc.
- **DATE OF NAME CHANGE:** 20040617

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** AETERNA LABORATORIES INC
- **DATE OF NAME CHANGE:** 20000503

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16**

**UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the month of December, 2025

Commission File Number: **001-38064**

**COSCIENS Biopharma Inc.**

(Translation of registrant's name into English)

**c/o Norton Rose Fulbright Canada, LLP**

**222 Bay Street, Suite 3000, PO Box 53**

**Toronto ON M5K 1E7**

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

On December 1, 2025, COSCIENS Biopharma Inc. (the "Company") issued a press release announcing an Exclusive Distribution Agreement with Wuzhou Drug International for Macrilen® in Hainan-Guangdong-Hong Kong-Macao Greater Bay Area and Singapore. A copy of the press release is attached to this Form 6-K as Exhibit 99.1 and is incorporated by reference herein. The press release contains forward-looking statements and includes cautionary statements identifying important factors that could cause actual results to differ materially from those in the forward-looking statements.

**Forward-Looking Statements**

The information in this Report on Form 6-K and the exhibit attached hereto and incorporated herein by reference include forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, specifically Section 27A of the U.S. Securities Act of 1933, as amended, Section 21E of the U.S. Securities Exchange Act of 1934, as amended, and under the provisions of Canadian securities laws. These forward-looking statements involve a number of known and unknown risks, uncertainties and other factors that could cause actual results and outcomes to be materially different from historical results or from any future results expressed or implied by such forward-looking statements.

Forward-looking statements include, but are not limited to, those relating to the Company's expectations regarding the anticipated benefits and synergies as well as the assets, cost structure, financial position, cash flows and growth prospects of the combined company.

Risks and factors that could cause actual results or outcomes to differ materially from expectations include, among others, the following:

● the
 Company's patented technologies and value-driving products, and development thereof;

● the
 extraction, production and commercialization of active ingredients from natural sources and our ability to successfully market related
 products;

● the
 successful development and marketing of our oat-based pipeline products, including oat-beta glucan, avenanthramides and beta glucan
 from yeast, as well as such products' capability to address unmet needs within the nutraceuticals markets;

● Macrilen®
 (macimorelin) and the Company's plans in respect of same, including commercialization.

● the
 Company's business strategy;

● the
 strategic decision to sunset the Company's Amyotrophic Lateral Sclerosis (ALS), AIM Biologicals and Delayed Clearance Parathyroid
 Hormone (DC-PTH) programs ;

● the
 transition to a new presidential administration in the United States, including the potential use and effects of tariffs to address
 the administration's policy goals, could materially impact our costs and revenues, as well as the macroeconomic framework in
 which we operate.

● the
 Company's positioning in its target markets;

● the
 Company's ability to accelerate the scale-up of PGX Technology towards commercial levels;

● expectations
 for completion of the Company's Edmonton facility and Natex Termitz facility;

● pre-clinical
 and clinical studies and trials and their expected timing and results, including the potential to bring certain products to market
 following such studies and trials;

● the
 ability of our pharmaceutical therapeutic assets to address unmet medical needs across a number of indications;

● management's
 assumptions, estimates and judgements;

● liquidity
 and capital resources;

● adequacy
 of our financial resources to finance operations and expenditure requirements;

● limitations
 on internal controls over financial reporting; and

● the
 plans, objectives, future outlook and financial position of the Company in general.

Additional risk factors that could cause actual results to differ materially include those risks identified in Item 3. "Key Information – Risk Factors" contained in the Company's most recent Annual Report on Form 20-F filed with the SEC and its other filings and submissions from time to time, including those containing its quarterly and annual results, with the SEC, which are available on the Company's website located at <u>www.cosciensbio.com</u>.

Many of these risks and factors are beyond the Company's control. The Company cautions you not to place undue reliance on these forward-looking statements. All written and oral forward-looking statements attributable to the Company or persons acting on their behalf, are qualified in their entirety by these cautionary statements. Moreover, unless required by law to update these statements, the Company will not necessarily update any of these statements after the date hereof, either to conform them to actual results or to changes in their expectation.

**DOCUMENTS INDEX**

---

| | |
|:---|:---|
| **Exhibit** | **Description** |
| 99.1 | [COSCIENS Announces Exclusive Distribution Agreement with Wuzhou Drug International for Macrilen® in Hainan-Guangdong-Hong Kong-Macao Greater Bay Area and Singapore](ex99-1.htm) |

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **COSCIENS Biopharma Inc.** | **COSCIENS Biopharma Inc.** |
| Date: December 1, 2025 | By: | */s/ Giuliano La Fratta* |
|  | Name: | Giuliano La Fratta |
|  | Title: | Chief Financial Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

![](ex99-1_001.jpg)

**COSCIENS Announces Exclusive Distribution Agreement with Wuzhou Drug International for Macrilen® in Hainan-Guangdong-Hong Kong-Macao Greater Bay Area and Singapore**

**TORONTO, ONTARIO, December 1, 2025** – COSCIENS Biopharma Inc. (TSX: CSCI) (FINRA: CSCIF) ("**COSCIENS**" or the "**Company**"), a life sciences company focused on pharmaceutical therapies, diagnostic products, and natural ingredients solutions, today announced that its wholly-owned subsidiary, Aeterna Zentaris GmbH, has entered into an exclusive distribution agreement with Wuzhou Drug International Trading Limited ("**Wuzhou**") for the commercialization of Macrilen® (macimorelin) in Hong Kong, Macao, Singapore, and the Chinese provinces of Guangdong and Hainan.

Under the terms of the agreement, Wuzhou will be responsible for the registration, importation, and commercialization of Macrilen® (macimorelin), the Company's oral diagnostic test for Adult Growth Hormone Deficiency ("**AGHD**"), within the designated territories. This partnership leverages the "Hong Kong and Macao Medicine and Equipment Connect" policy, allowing for expedited market access in the Guangdong-Hong Kong-Macao Greater Bay Area. The agreement is for an initial ten-year term and includes a commitment by Wuzhou for a minimum initial order of approximately €800,000.

**COSCIENS Management Commentary**

Dr. Matthias Gerlach, Senior Vice-President and Managing Director of Aeterna Zentaris GmbH commented: "We are very pleased to partner with Wuzhou, with their proven track record in the Greater China region and Southeast Asia, deep regulatory expertise and strong commercial presence in the Greater Bay Area and Singapore specifically. This agreement represents a key step in our strategy to unlock the global potential of Macrilen® and to build sustainable, long -term revenue streams." Dr. Gerlach continued, "Entering these dynamic Asian markets allows us to address a significant unmet need for a convenient, oral diagnostic option for patients suspected of suffering from growth hormone deficiency. We look forward to working closely with the Wuzhou team to bring this innovative diagnostic test to patients and healthcare providers across the region and ultimately helping improve patient outcomes through earlier and more accurate diagnosis."

**Statement from Wuzhou Drug International**

Mr. Zheng Guo Shang, General Manager of Wuzhou commented, "Wuzhou is dedicated to introducing high-quality, innovative healthcare solutions to the Greater China and Southeast Asian markets. We identify a strong strategic fit for Macrilen® within our specialty portfolio, particularly given the clear demand for a reliable and patient-friendly diagnostic tool for AGHD. We are eager to leverage our regulatory capabilities and hospital network to navigate the approval pathways in Hong Kong, Macao, and the pilot zones of Guangdong and Hainan, ensuring that patients have access to this gold-standard diagnostic as swiftly as possible."

![](ex99-1_001.jpg)

**About COSCIENS Biopharma Inc. and Macrilen®**

COSCIENS is a life science company with a diverse portfolio focused on the development of natural, plant-based active ingredients and engaged in the commercialization of pharmaceutical and diagnostic products. COSCIENS' natural active ingredient business leverages the Company's proprietary manufacturing and extraction technologies to develop Avenanthramides and Beta Glucan active ingredients currently used in leading skincare brands worldwide.

Macrilen® (macimorelin), COSCIENS' lead pharmaceutical product, is a ghrelin agonist that stimulates the secretion of growth hormone from the pituitary gland and is the first and only U.S. Food and Drug Administration ("FDA") and European Medicines Agency ("EMA") approved oral test indicated for the diagnosis of AGHD.

**About Wuzhou Drug International Trading Limited**

Wuzhou Drug International Trading Limited is a pharmaceutical trading and services company headquartered in Macao. The company specializes in the introduction, registration, and distribution of innovative medicines, with a focus on ophthalmology, rare diseases, and specialty diagnostics across the Greater Bay Area (including Guangdong, Hong Kong, and Macao) and Singapore.

**Forward-Looking Statements**

Certain statements in this news release, referred to herein as "forward-looking statements", constitute "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995, as amended, and "forward-looking information" under the provisions of Canadian securities laws. All statements, other than statements of historical fact, that address circumstances, events, activities, or developments that could or may or will occur are forward-looking statements. When used in this news release, words such as "anticipate", "assume", "believe", "could", "expect", "forecast", "future", "goal", "guidance", "intend", "likely", "may", "would" or the negative or comparable terminology as well as terms usually used in the future and the conditional are generally intended to identify forward-looking statements, although not all forward-looking statements include such words. Forward-looking statements in this news release include, but are not limited to, statements relating to the expectations regarding the anticipated benefits of the distribution agreement with Wuzhou.

These statements are based on current expectations and assumptions, including factors or assumptions factors or assumptions that were applied in drawing a conclusion or making a forecast or projection, including assumptions based on historical trends, current conditions and expected future developments. Since forward-looking statements relate to future events and conditions, by their very nature they require making assumptions and involve inherent risks and uncertainties. The Company cautions that although it is believed that the assumptions are reasonable in the circumstances, these risks and uncertainties give rise to the possibility that actual results may differ materially from those expressed or implied by such forward-looking statements, including but not limited to the factors described in "Risks Relating to Us and Our Business" in the Company's Annual Report on Form 20-F for the year ended December 31, 2024. Given these risks, undue reliance should not be placed on these forward-looking statements, which apply only as of their dates. We disclaim any obligation to update any such risks or uncertainties or to publicly announce any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, unless required to do so by a governmental authority or applicable law.

**Issuer Contact:**

Peter H. Puccetti

Interim CEO and Chairman of the Board

pp@cosciensbio.com

Giuliano La Fratta

Chief Financial Officer

glafratta@cosciensbio.com

**Investor Contact:**

IR@cosciensbio.com